CF
FENC icon

Corebridge Financial’s Fennec Pharmaceuticals FENC Stock Holding History

Corebridge Financial’s Portfolio FENC Stock Details FENC Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		– Sell
-11,664
Closed -$71K – 973
2025
Q1 		$71K Buy
11,664
+11
+0.1% +$71 ﹤0.01% 2609
2024
Q4 		$73.6K Sell
11,653
-880
-7% -$4.51K ﹤0.01% 2698
2024
Q3 		$62.7K Sell
12,533
-77
-0.6% -$445 ﹤0.01% 2802
2024
Q2 		$77K Buy
+12,610
New +$105K ﹤0.01% 2737

Other funds holding FENC

SCA
Southpoint Capital Advisors New York $4.86B AUM 34.09% 1-Year Est. Return
SCM
Solas Capital Management Darien, Connecticut $174M AUM 6.33% 1-Year Est. Return
RA
Rosalind Advisors Toronto, Ontario, Canada $249M AUM 80.12% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
ACM
AIGH Capital Management Baltimore, Maryland $733M AUM 327.32% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
HFA
Harbert Fund Advisors Birmingham, Alabama $3.03M AUM 40.55% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Corebridge Financial's FENC Position: Q2 2025 in Review

Corebridge Financial sold out of Fennec Pharmaceuticals (FENC) in Q2 2025, closing a stake of 11,664 shares — an estimated $71K sold.

Corebridge Financial first reported a position in FENC in Q2 2024 and held it in 4 quarters. The position peaked at $77K in Q2 2024. 78 funds tracked by Wall St. Rank hold FENC as of Q2 2025.

  • Corebridge Financial reported no remaining Fennec Pharmaceuticals position as of Q2 2025 after selling out during the quarter.
  • Corebridge Financial sold 11,664 Fennec Pharmaceuticals shares in Q2 2025, an estimated $71K.
  • Corebridge Financial first reported a position in Fennec Pharmaceuticals in Q2 2024 and held it in 4 quarters.
  • Corebridge Financial's Fennec Pharmaceuticals position peaked at $77K in Q2 2024.
  • 78 funds tracked by Wall St. Rank held Fennec Pharmaceuticals as of Q2 2025.

Based on Corebridge Financial's 13F filing for Q2 2025, filed 12 Aug 2025.